Systemic inflammation and nutritional insufficiency in palliative cancer patients

Abstract

Aim. To study the relationship between the symptoms of nutritional insufficiency and systemic inflammation in cancer palliative patients.

Methods. 106 palliative cancer patients were examined at Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine: 54 (50.9%) men and 52 (49.1%) women aged 61 [54; 67] years. All patients underwent laboratory and instrumental examination within the approved standards of specialized medical care. Systemic inflammation was assessed by the levels of acute phase proteins (C-reactive protein, fibrinogen). The study of integrated clinical and laboratory, somatometric parameters was carried out. The nutritional risk index was assessed.

Results. Palliative cancer patients showed a statistically significant decrease in the concentration of hemoglobin, lymphocytes, and albumin. The activation of systemic inflammation that manifested by hyperfibrinogenemia and an increase in the level of C-reactive protein was revealed. The study of somatometric parameters revealed a statistically significant decrease in body mass index, shoulder circumference, subscapular skinfold thickness, and a tendency to reduce lean body mass. The nutritional risk index assessment showed mild nutritional insufficiency in 22 (20.8%) of the examined patients and severe nutritional insufficiency in 28 (26.4%) patients. The maximum diagnostic significance of the level of C-reactive protein for prediction the nutritional insufficiency was achieved at 80.4% sensitivity and 52.7% specificity (AUC=0.671, 95% confidence interval [0.573; 0.759], p=0.001), which corresponded to a C-reactive protein threshold of 31 mg/l.

Conclusion. 50 (47.2%) of the examined patients showed signs of nutritional insufficiency, a statistically significant decrease in hemoglobin and albumin concentration, as well as lymphocyte count, activation of systemic inflammation, manifested by hyperfibrinogenemia, and an increase in the level of C-reactive protein; it was revealed a statistically significant relationship between C-reactive protein level and malnutrition.

Keywords

nutritional insufficiency / systemic inflammation / palliative care

References

[1] Khoronenko V.E., Sergienko A.D., Mandryka E.A., Yagubyan R.S., Khomyakov V.M., Ryabov A.B. Assessment of nutritional status in cancer patients. Trudnyy patsient. 2018; 16 (5): 22–26. (In Russ.)

[2] Хороненко В.Э., Сергиенко А.Д., Мандрыка Е.А., Ягубян Р.С., Хомяков В.М., Рябов А.Б. Оценка нутритивного статуса у онкологических больных. Трудный пациент. 2018; 16 (5): 22–26.

[3] Make­eva T.K., Galkin A.A. Nutritional status of the gastric cancer patients. Vestnik Sankt-Peterburgskogo universiteta. Meditsina. 2008; (S1): 105–117. (In Russ.)

[4] Макеева Т.К., Галкин А.А. Трофологический статус больных раком желудка. Вестн. Санкт-Петербургского ун-та. Медицина. 2008; (S1): 105–117.

[5] Snegovoy A.V., Besova N.S., Veselov A.V., Kravzhov S.A., Larionova V.B., Selyichuk V.Yu., Sukurenko V.P., Khomyakov V.M. Practice recommendations p for nutritional support in cancer patients. Zlokachestvennye opukholi. 2016; 4 (S2): 434–450. (In Russ.) DOI: 10.18027/2224-5057-2016-4s2-434-450.

[6] Снеговой А.В., Бесова Н.С., Веселов А.В., Кравцов С.А., Ларионова В.Б., Сельичук В.Ю., Сокуренко В.П., Хомяков В.М. Практические рекомендации по нутритивной поддержке у онкологических больных. Злокачеств. опухоли. 2016; 4 (S2): 434–450. DOI: 10.18027/2224-5057-2016-4s2-434-450.

[7] Babckov O.V., Rudakov D.A., Luft V.M., Zakharenko A.A., Bezmozgin B.G., Surov D.A., Ten O.A., Lapitskiy A.V. Nutrition support of patients with colorectal cancer, complicated perifocal inflammation and abscess formation. Medline.ru. Rossiyskiy biomeditsinskiy zhurnal. 2014; 15 (1): 1–7. (In Russ.)

[8] Бабков О.В., Рудаков Д.А., Луфт В.М., Захаренко А.А., Безмозгин Б.Г., Суров Д.А., Тен О.А., Лапицкий А.В. Нутриционная поддержка больных колоректальным раком, осложнённым перифокальным инфильтратом и абсцессом. Medline.ru. Рос. биомед. ж. 2014; 15 (1): 1–7.

[9] Mayne S.T., Playdon M.C., Rock C.L. Diet, nutrition, and cancer: past, present and future. Nature Rev. Clin. Oncol. 2016; 13 (8): 504. DOI: 10.1038/nrclinonc.2016.24.

[10] Capra S., Ferguson M., Ried K. Cancer: impact of nutrition intervention outcome — nutrition issues for patients. Nutrition. 2001; 17 (9): 769–772. DOI: 10.1016/S0899-9007(01)00632-3.

[11] Laird B.J., McMillan D.C., Fayers P., Fearon K., Kaasa S., Fallon M.T., Klepstad P. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist. 2013; 18 (9): 1050–1055. DOI: 10.1634/theoncologist.2013-0120.

[12] Snegovoj A.V., Kono­nenko I.B., Larionoba V.B., Maznyuk L.V., Saltanov A.I., Selchyuk V.Yu. Practice recommendations for the correction of anore­xia-cachexia syndrome in cancer patients. Zlokachestvennye opukholi. 2015; 4 (S): 412–416. (In Russ.)

[13] Снеговой А.В., Кононенко И.Б., Ларионова В.Б., Манзюк Л.В., Салтанов А.И., Сельчук В.Ю. Практические рекомендации по коррекции синдрома анорексии-­кахексии у онкологических больных. Злокачеств. опухоли. 2015; 4 (S): 412–416.

[14] Grafetstätter M., Hüsing A., Maldonado S.G., Sookthai D., Johnson Th., Pletsch-Borba L., Katzke V.A., Hoffmeister M., Bugert P., Kaaks R., Kühn T. Plasma fibrinogen and sP-selectin are associated with the risk of lung cancer in a prospective study. Cancer Epidemiol. Prevent. Biomarkers. 2019; 28 (7): 1221–1227. DOI: 10.1158/1055-9965.EPI-18-1285.

[15] Ryan A.M., Power D.G., Daly L., Cushen S.J., Bhua­challa Ē.Ní., Prado C.M. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proceedings of the Nutrition Society. 2016; 75 (2): 199–211. DOI: 10.1017/S002966511500419X.

[16] Matthys P., Billiau A. Cytokines and cachexia. Nutrition. 1997; 13 (9): 763–770. DOI: 10.1016/S0899-9007(97)00185-8.

[17] Tan B.H.L., Birdsell L.A., Martin L., Baracos V.E., Fearonet K.C.H. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 2009; 15 (22): 6973–6979. DOI: 10.1158/1078-0432.CCR-09-1525.

[18] Donskova Ju.S. Diagnostic and prognostic role of biomarkers of systemic inflammatory response and sepsis in oncology. Onkohirurgiya. 2012; 4 (1): 65–72. (In Russ.)

[19] Донскова Ю.С. Диагностическое и прогностическое значение биологических маркёров системной воспалительной реакции и сепсиса в онкохирургии. Онкохирургия. 2012; 4 (1): 65–72.

[20] Dolan R.D., McSorley S.T., Horgan P.G., Laird L., McMillan D.C. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit. Rev. Oncol./Hematol. 2017; (116): 134–146. DOI: 10.1016/j.critrevonc.2017.06.002.

[21] Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; (40): 373–383. DOI: 10.1016/0021-9681(87)90171-8.

[22] De Kock I., Mirhosseini M., Lau F., Thai V., Dow­ning M., Quan H., Lesperance M., Yang J. Conversion of Karnofsky performance status (KPS) and eastern coope­rative oncology group performance status (ECOG) to palliative performance scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J. Palliative Care. 2013; (29): 163–169. DOI: 10.1177/082585971302900305.

[23] Kaprin A.D., Abuzarova G.R., Khoronenko V.E., Alekssyeva G.S., Kostin A.A., Starinskii V.V., Alekseev B.Ya., Aleksandrova B.Ya. Farmakoterapiya hronicheskogo bolevogo sindroma u onkologicheskih pacientov. (Pharmacotherapy of chronic pain syndrome in cancer patients.) M.: MNIOI im. P.A. Gercena — filial FGBU FMIC im. P.A. Gercena Minzdrava Rossii. 2015; 48. (In Russ.)

[24] Каприн А.Д., Абузарова Г.Р., Хороненко В.Э., Алексеева Г.С., Костин А.А., Старинский В.В., Алексеев Б.Я., Александрова Л.М. Фармакотерапия хронического болевого синдрома у онкологических пациентов. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ ФМИЦ им. П.А. Герцена Минздрава России. 2015; 48.

[25] Andreoli A., De Lorenzo A., Cadeddu F., Iacopino L., Grande M. New trends in nutritional status assessment of cancer patients. Eur. Rev. Med. Pharmacol. Sci. 2011; (15): 469–480. PMID: 21744742.

[26] Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., Fearon K., Hütterer E., Isenring E., Kaasa S., Krznaric Z., Laird B., Larsson M., Laviano A., Mühlebach S., Muscaritolim M., Oldervoll L., Ravasco P., Solheim T., Strasser F., Schueren M., Preiseret J.-Ch. ­ESPEN guidelines on nutrition in cancer patients. Clin. Nutrition. 2017; 36 (1): 11–48. DOI: 10.1016/j.clnu.2016.07.015.

[27] Savushkin A.V., Khachaturova E.A., Kapitanov M.V., Eroshkina T.D. Assesment of malnutrition in elderly and senior patients with colorectal cancer. Koloproktologiya. 2016; (3): 43–48. (In Russ.)

[28] Савушкин А.В., Хачатурова Э.А., Капитанов М.В., Ерошкина Т.Д. Оценка нутритивной недостаточности у пациентов пожилого и старческого возраста, страдающих колоректальным раком. Колопроктология. 2016; (3): 43–47.

[29] Arends J., Baracos V., Bertz H., Bozzetti F., Calder P.C., Deutz N.E.P., Erickson N., Laviano A., Lisanti M.P., Lobo D.N., McMillan D.C., Muscaritoli M., Ocken­ga J., Pirlich M., Strasser F., Schueren M., VanGossum A., Vaupel P., Weimann A. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutrition. 2017; 36: 1187–1196. DOI: 10.1016/j.clnu.2017.06.017.

[30] Anatole C., Hebuterne X., Coriat R., Durand J.-Ph., Mir O., Mateus Ch., Cacheux W., Lemarie E., Michallet M., de Montreuil C.B. Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status. Supportive Care in Cancer. 2011; 19 (7): 869–875. DOI: 10.1007/s00520-011-1122-z.

[31] Donohoe C.L., Ryan A.M., Reynolds J.V. Cancer cachexia: mechanisms and clinical implications. Gastroente­rol. Res. Pract. 2011; (1): 5. DOI: 10.1155/2011/601434.

[32] Farhangfar A., Makarewicz M., Ghosh S., Jha N., Scrimger R., Gramlich L., Baracos V. Nutrition impact symptoms in a population cohort of head and neck cancer patients: multivariate regression analysis of symptoms on oral intake, weight loss and survival. Oral Oncol. 2014; 50 (9): 877–883. DOI: 10.1016/j.oraloncology.2014.06.009.

[33] Kostyukevich O.I., Sviridov S.V., Rylova A.K., Rylova N.V., Korsunskaya M.I., Kolesnikova E.A. Malnutrition: from pathogenesis to current methods for diagnosis and treatment. Terapevticheskii arkhiv. 2017; 12 (2): 216–225. (In Russ.) DOI: 10.17116/terarkh20178912216-225.

[34] Костюкевич О.И., Свиридов С.В., Рылова А.К., Рылова Н.В., Корсунская М.И., Колесникова Е.А. Недостаточность питания: от патогенеза к современным методам диагностики и лечения. Терап. архив. 2017; 12 (2): 216–225. DOI: 10.17116/terarkh20178912216-225.

[35] Nitenberg G., Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit. Rev. Oncol. Hematol. 2000; 34 (3): 137–168. DOI: 10.1016/s1040-8428(00)00048-2.

[36] Anandavadivelan P., Brismar T.B., Nilsson M., Johar A.M., Martin L. Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin. Nutrition. 2016; 35 (3): 724–730. DOI: 10.1016/j.clnu.2015.05.011.

[37] Misnikova I.V., Kovaleva Yu.A., Klimina N.A. Sarcopenic obesity. RMZh. 2017; 25 (1): 24–29. (In Russ.)

[38] Мисникова И.В., Ковалёва Ю.А., Климина Н.А. Саркопеническое ожирение. РМЖ. 2017; 25 (1): 24–29.

[39] Al-Jaouni R., Schneider S.M., Rampal P., Hébuterne X. Effect of age on substrate oxidation during total parenteral nutrition. Nutrition. 2002; 18 (1): 20–25. DOI: 10.1016/S0899-9007(01)00697-9.

[40] Sargento L., Longo S., Lousada N., dos Reis R.P. The importance of assessing nutritional status in elderly patients with heart failure. Curr. Heart Failure Rep. 2014; 11 (2): 220–226. DOI: 10.1007/s11897-014-0189-5.

RIGHTS & PERMISSIONS

Kurchenkova O.V., Kharlamova U.V., Vazhenin A.V., Abdalov A.O.